AbbVie said its board unanimously elected CEO Robert A. Michael, who is also a director, to succeed Richard A. Gonzalez as chairman, effective July 1, 2025. The board vote took place on February 13, 2025.

1. 01

   AbbVie said its board unanimously elected CEO Robert A. Michael, who is also a director, to succeed Richard A. Gonzalez as chairman, effective July 1, 2025. The board vote took place on February 13, 2025.

2. 02

   The company said Richard A. Gonzalez, who has served as chairman since the company's formation in 2013, will retire from the board effective July 1, 2025. He previously served as the company's chief executive officer.

3. 03

   AbbVie said Glenn F. Tilton informed the company on February 13, 2025 of his decision to retire from the board, effective July 1, 2025. He served as lead independent director from 2013 to 2024, and Roxanne S. Austin succeeded him in July 2024.

4. 04

   AbbVie said Robert A. Michael was president and chief operating officer before becoming CEO, and was appointed vice chairman and president in 2022, vice chairman, finance and commercial operations in 2021, and chief financial officer in 2018. The press release said his career spans more than 32 years.

Analysis scope · Filing body and confirmed press-release exhibitWe analyzed the filing body and confirmed exhibits. This is not a review of other exhibits, investor presentations or the full earnings call.

AI summarized the filing and translated the summary into English; it may differ from the original. For reference only, not investment advice. AI translated the published Korean report into English. Figures are copied as filed, not recalculated.

Original filing

The filing as submitted to SEC EDGAR. You can check the figures and statements of this summary against it.